1CP
HQL

1607 Capital Partners’s abrdn Life Sciences Investors HQL Stock Holding History

1607 Capital Partners’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
76,387
-27,676
-27% -$489K 0.13% 104
2026
Q1 		$1.69M Sell
104,063
-11,007
-10% -$184K 0.12% 104
2025
Q4 		$1.93M Sell
115,070
-7,100
-6% -$119K 0.13% 87
2025
Q3 		$1.89M Sell
122,170
-39,801
-25% -$545K 0.14% 85
2025
Q2 		$2.07M Sell
161,971
-19,000
-10% -$234K 0.17% 92
2025
Q1 		$2.3M Sell
180,971
-66,176
-27% -$896K 0.19% 82
2024
Q4 		$3.24M Sell
247,147
-102,354
-29% -$1.48M 0.26% 79
2024
Q3 		$5.27M Sell
349,501
-69,778
-17% -$1.06M 0.48% 59
2024
Q2 		$5.94M Sell
419,279
-62,100
-13% -$840K 0.53% 56
2024
Q1 		$6.56M Buy
481,379
+1,200
+0.2% +$16.6K 0.54% 55
2023
Q4 		$6.46M Buy
480,179
+764
+0.2% +$9.4K 0.45% 65
2023
Q3 		$5.98M Hold
479,415
– – 0.45% 61
2023
Q2 		$6.49M Buy
479,415
+15,700
+3% +$217K 0.47% 59
2023
Q1 		$6.46M Buy
463,715
+73,984
+19% +$1.06M 0.45% 61
2022
Q4 		$5.54M Buy
389,731
+304,830
+359% +$4.42M 0.38% 69
2022
Q3 		$1.16M Buy
+84,901
New +$1.27M 0.09% 115
2021
Q4 		– Sell
-10,000
Closed -$208K – 116
2021
Q3 		$208K Sell
10,000
-100,901
-91% -$2.16M 0.01% 105
2021
Q2 		$2.38M Sell
110,901
-48,842
-31% -$986K 0.11% 87
2021
Q1 		$3.15M Sell
159,743
-43,245
-21% -$891K 0.15% 93
2020
Q4 		$4.01M Hold
202,988
– – 0.2% 78
2020
Q3 		$3.57M Buy
202,988
+27,964
+16% +$501K 0.19% 82
2020
Q2 		$3.14M Buy
175,024
+101,513
+138% +$1.74M 0.17% 84
2020
Q1 		$1.1M Buy
+73,511
New +$1.2M 0.07% 113

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

1607 Capital Partners's HQL Position: Q2 2026 in Review

1607 Capital Partners reduced its abrdn Life Sciences Investors (HQL) stake by 27% in Q2 2026, selling an estimated $489K and leaving 76,387 shares worth $1.53M. The position accounts for 0.13% of the portfolio, ranked #104.

1607 Capital Partners first reported a position in HQL in Q1 2020 and has held it in 23 quarters since. The position peaked at $6.56M in Q1 2024. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • 1607 Capital Partners held 76,387 shares of abrdn Life Sciences Investors worth $1.53M as of Q2 2026.
  • 1607 Capital Partners sold 27,676 abrdn Life Sciences Investors shares in Q2 2026, an estimated $489K.
  • abrdn Life Sciences Investors made up 0.13% of 1607 Capital Partners's portfolio in Q2 2026, its #104 holding.
  • 1607 Capital Partners first reported a position in abrdn Life Sciences Investors in Q1 2020 and has held it in 23 quarters since.
  • 1607 Capital Partners's abrdn Life Sciences Investors position peaked at $6.56M in Q1 2024.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on 1607 Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.